Sign Out
Posology: Adults: The recommended dose of Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food [see Pharmacology: Pharmacokinetics under Actions]. Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset [see Pharmacology: Pharmacodynamics: Clinical efficacy and safety under Actions].
Take the drug for 5 consecutive days of the course of treatment and continue quarantine in accordance with public health advice. To eliminate the virus as much as possible and reduce the spread of infection SARS-CoV-2.
Restrictions on Use: The safety and efficacy of Molnupiravir when administered for periods longer than 5 days have not been established.
Molnupiravir not to be used in the case of before or after exposure to prevent COVID-19.
Molnupiravir not to be used in the case of any indication other than the treatment of COVID-19.
Missed dose: If the patient misses a dose of Molnupiravir within 10 hours of the time it is usually taken, the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.
In the event that the patient has to be hospitalized due to COVID-19 with severe or critical condition after starting treatment with Laquefrio Patients should receive the drug for the full 5-day course of treatment, at the discretion of their healthcare provider.
Patient group selection: The following medical conditions or other factors put adult patients 18 years of age or older at higher risk of progression to COVID-19 with severe symptoms: Age >60 years; Active cancer (This excludes non-invasive cancers that are not associated with immunosuppression or significant morbidity/mortality [e.g. melanoma basal cell carcinomas]); Chronic kidney disease (This does not include patients requiring dialysis or those with a decrease in eGFR <30ml/min/1.73 m2 [see Pharmacology: Pharmacokinetics under Actions]); Chronic obstructive pulmonary disease; Obesity (BMI ≥ 30 kg/m2); Severe heart conditions, including congestive heart failure, coronary artery disease or cardiomyopathies; Diabetes.
Special populations: Elderly: No dose adjustment is recommended for geriatric patients.
Renal impairment: No dose adjustment is required for patients with renal impairment [see Pharmacology: Pharmacokinetics under Actions].
Hepatic impairment: No dose adjustment is required for patients with hepatic impairment [see Pharmacology: Pharmacokinetics under Actions].
Paediatric population: Molnupiravir is not approved for use in pediatric patients under 18 years of age.
From repeated drug toxicity studies with a period of 3 months in rats bone and cartilage toxicity was found. The safety and efficacy of molnupiravir in pediatric patients have not been studied. [See Use in Children: Bones and cartilage toxicity under Precautions and Pharmacology: Toxicology: Preclinical safety data under Actions.]
Method of administration: For oral use.
Molnupiravir 200 mg capsules can be taken with or without food.
The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed.
